2013 news releases and statements

21/05/2013
ABPI to take lead role in representing vaccine industry
01/05/2013
ABPI response to European General Court's ruling of 30 April 2013
01/05/2013
ABPI comment on EMA's clinical trial groups
29/04/2013
ABPI response to today's article in the Independent
26/04/2013
ABPI response to FT article on health of UK pharmaceutical industry
25/04/2013
NHS under-spend on medicines is limiting patient care
05/04/2013
Pharmaceutical industry takes the lead on transparency
03/04/2013
ABPI reaction to Indian Supreme Court ruling
21/03/2013
ABPI statement on Government’s response to Health Select Committee’s report on future role of NICE
20/03/2013
ABPI response to Budget 2013
18/03/2013
ABPI statement on AstraZeneca announcement
14/03/2013
Exciting new addition to ABPI membership
11/03/2013
ABPI statement on antimicrobial resistance
11/03/2013
ABPI statement on Science and Technology Select Committee’s inquiry into clinical trials
27/02/2013
ABPI announces new clinical trial transparency measures
26/02/2013
ABPI Chief Executive welcomes proposed changes to Patents Act
15/02/2013
Stakeholder engagement on value-based pricing
08/02/2013
ABPI Scotland welcomes investment in drug discovery
07/02/2013
Steve Oldfield appointed to influential Medicines Access Group
07/02/2013
ABPI's relationship with Luther Pendragon
07/02/2013
ABPI response to Times article on patents
05/02/2013
ABPI statement on GSK signing up to the Alltrials campaign
05/02/2013
ABPI membership continues to grow
05/02/2013
ABPI response to Lancet editorial on collaboration guidance
01/02/2013
Engagement with Dr Ben Goldacre
01/02/2013
ABPI response to questions from Sense about Science about alltrials.net
01/02/2013
ABPI response to Guardian article on antimicrobial resistance
31/01/2013
ABPI response to GMC's new prescribing guidance
31/01/2013
ABPI and PM Society cement ties with joint working agreement
28/01/2013
Consultation launched to promote greater transparency between healthcare professionals and industry
25/01/2013
ABPI statement on pricing negotiations
25/01/2013
ABPI comment on the ECHOUTCOME project
24/01/2013
ABPI statement on antimicrobial medicines
18/01/2013
ABPI statement on alltrials.net
15/01/2013
ABPI responds to announcement of a new fund in Scotland for people with rare diseases
10/01/2013
New Innovation Scorecard shows the extent of regional variation in the NHS

Print this page

Get in touch

Please choose the subject of your enquiry from the list below:

Enter the above code here:

Can't read? Try different words.

Submit

I am happy for ABPI to keep my details on file and to send me details of future ABPI work and services. ABPI will not sell your data to any third party or send you any information about products or services that ABPI has no direct connection with.

The Association of the British Pharmaceutical Industry

7th floor, Southside, 105 Victoria Street,
London, SW1E 6QT
Telephone +44 (0) 870 890 4333
ABPI Cymru Wales
ABPI Northern Ireland
ABPI Scotland

The Prescription Medicines Code of Practice Authority (PMCPA) is responsible for administering the ABPI Code of Practice for the Pharmaceutical Industry at arm's length of the ABPI itself.

The Office of Health Economics (OHE) provides independent research, advisory and consultancy services on policy implications and economic issues within the pharmaceutical, health care and biotechnology sectors.